Wells Pharma of Houston, LLC, Houston, TX

Is Wells Pharma of Houston, LLC registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Wells Pharma of Houston, LLC in Houston, TX, first registered Mar 9, 2020 and most recently registered Oct 29, 2026.

Does Wells Pharma of Houston, LLC hold a Texas pharmacy license?

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. The California State Board of Pharmacy also lists nonresident license NSF 144 for Wells Pharma Of Houston Llc, Houston, TX, status Delinquent, as of Nov 6, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0012567 for Wells Pharma of Houston, LLC, HOUSTON, TX, status Active and license AA-0010071 for Wells Pharma of Houston, LLC, HOUSTON, TX, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012826 for Wells Pharma of Houston, LLC, Houston, TX, status Active, as of Nov 10, 2026.

Has Wells Pharma of Houston, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Nov 7, 2025) and 2 FMD-145 letters (Jan 10, 2022 and Apr 18, 2023) for Wells Pharma of Houston, LLC. Texas board disciplinary orders: not checked, because the board’s file flags orders only on a license, and no license matched this name and city.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Wells Pharma of Houston, LLC; Wells Pharma of Houston LLC
Location
Houston, TX
Type as FDA labels it
503B
FDA 503B list
Listed as Wells Pharma of Houston, LLC
Form 483s on FDA’s actions page
4
Warning letters on FDA’s actions page
1
Latest action on that page
Apr 14, 2026
FDA Data Dashboard inspections
3 inspections: 1 OAI, 2 VAI; 4 published Form 483s
Form 483 text on this page
3 Form 483s, 10 observations
State board records
No exact match

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Wells Pharma of Houston LLC, a 503B facility, with 7 dated actions.

Document
Apr 14, 2026Amended Form 483Amended 483 Issued 04/14/2026fda.gov
Nov 7, 2025Warning letterWarning Letter Issued 11/07/2025fda.gov
Mar 28, 2025Form 483483 issued 03/28/2025fda.gov
Apr 18, 2023FMD-145 letterFMD-145 Letter Issued 4/18/2023Not linked by FDA
Dec 14, 2022Form 483483 Issued 12/14/2022FDA copy (archived)
Jan 10, 2022FMD-145 letterFMD-145 Letter Issued 01/10/2022Not linked by FDA
Jun 17, 2021Form 483483 Issued 06/17/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Wells Pharma of Houston LLC, Houston, TX (FEI number 3016710931), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Mar 28, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30167109311266232
Dec 14, 2022Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30167109311193883
Jun 17, 2021Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30167109311144681

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 10 numbered observations in all, across 3 inspections ending Jun 17, 2021 to Apr 13, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Mar 17, 2026 to Apr 13, 2026: 6 observations

Firm on the cover
Wells Pharma of Houston LLC, 9265 Kirby Dr, Houston, TX 77054 -2520
FEI number
3016710931
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

A. Your firm's compounding technician was observed removing the bottle of sterile <Redacted B4> from the inside of the ISO 5 LAFH, to the outside within the ISO 7 Cleanroom to disinfect their sterile <Redacted B4> gloves and failing to re-disinfect the bottle of sterile <Redacted B4> prior to returning it to the ISO 5 LAFH. Your firm's procedure Aseptic Material Transfer from CHC Area into Classified Areas, HOU­OPS-017, Revision 5 fail to adequately define a method for the transfer of sterile <Redacted B4> bottles into and out of the ISO 5 LAFH.

B. Your firm's compounding technicians were observed using hard to clean and disinfect pen within the ISO 7 Cleanroom to write within each production batch record that has the potential of being source of microorganism contamination transfer from the technician's sterile gloves into the ISO 5 LAFH.

C. Your firm's dynamic ISO 5 LAFH smoke studies were found to be inadequate. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that in-process materials and drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, your firm's quality unit failed to provide an adequate scientific rational for changing your contract testing laboratory pH test method specification from <Redacted B4> and changed to <Redacted B4> a specification of <Redacted B4> with BUDs of <Redacted B4> or 7- 5 days. There have been approximately <Redacted B4> out of <Redacted B4> batches of CeFazolin lots compounded between September 2025 to April 2, 2026 been distributed. For example, your firm initiated deviation, DEV-HOU-2025-068 dated 15-Sep-25 (Classification <Redacted B4> documenting Out-of-Specification (OOS) investigation EMPM-HOU-2025-062 to assess the pH levels of Cefazolin lg reconstituted in l0mL SWFI using a 10mL <Redacted B4> syringe, and Cefazolin 2g reconstituted in 20mL SWFI using a 30mL <Redacted B4> syringe. ...

Read the full 483 (PDF on fda.gov)

Observation 3

The written stability testing program is not followed.

Specifically, your firm's quality unit approved stability program for the fmished drug, CeFazolin is inadequate. For example,

A. Your firm's 4/12/2021 stability report for 3 different lots documented a pH specification of <Redacted B4> and CeFazolin assay specification of <Redacted B4> for CeFazolin 1g in SWFI 10 mL, l 0mL syringe, NDC 73702-131-10.

AM ENDMENT 1

1. Your record reported pH results that exceeded the documented specification at 30 days (pH 6.3/6.2/6.2), and CeFazolin assay documented results as low as 89 .1 % at 60 days. Your firm's contract testing laboratory reported, "Physical and chemical data for Cefazolin has demonstrated that Cefazolin in the present formula and packaging did not meet client specification through 75 days at refrigerated storage conditions". Your firm's quality unit failed to provide a document containing written actions taken to correct the deficiencies reported by your approved contract testing laboratory. Your firm's quality unit provided no additional stability report in support of the finished drug products meeting the written product specification.

2. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Drug products failing to meet established specifications and quality control criteria are not rejected.

Specifically, during a review of your firm's compounded and distributed finished drug products, I found your firm's quality unit released and distributed, Lot# 091625104652129, Expiry 1/16/2026 for Dextrose 50% (500MG/ML) Repackaged 50M <Redacted B4> Syringe Injectable 500MG/ML, which underwent contract laboratory testing, using an incorrect USP monograph pH test method. The pH results were found to be within specification using the incorrect test method. Due to a delay and inadequacy of an investigation by your firm's quality unit into the pH failure of the two (2) different batches, Lot # 091625104652129 was released and distributed. The quality unit's investigation was not expanded to include a review of other finished drug products to assess the potential of contract testing laboratory test method not being accurate until this inspection's discussions with management.

Observation 5

Strict control is not exercised over labeling issued for use in drug product labeling operations.

Specifically, during a walk-through of your firm's Labeling Production Area, I found an unsecured black storage filing cabinet containing issued printed CeFazolin labels for production use. Your firm's pharmacist and quality unit reported the key location for the unsecure unlocked cabinet was unknown at the time of the site walk-through. The area supervisor reported that the labels were removed from the cabinet at the end of the shift and returned to the label printing cage. A review of your written procedures, Labeling Procedure, HOU-OPS-019, Revision 1; and Label Control, HOU-OPS-020, Revision l found the discussed process for label removal at shift end was not written within your firm's procedures. The firm's quality unit was unable to provide documentation of printed labels being removed from the unsecured black cabinet and being returned to the returned to the label printing cage.

AM ENDMENT 1

This is a repeat observation.

Observation 6

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically,

A. Your firm's quality unit initiated CAPA HOU-2025-012 failed to adequately investigate and define corrections to secure and control finished product labeling and prevent mix-up within your firm's product labeling production area. For example, an unsecured cabinet containing CeFazolin labels was found in the labeling production area. Your firm's quality unit initiated CAPA-HOU-2026-008 after being made aware on March 17, 2026 during the labeling productions area walk-through.

C. Your firm's Quality unit failed to ensure your firm's labeling procedures, Labeling Procedure, HOU-OPS-019, Revision 1; and Label Control, HOU-OPS-020, Revision !adequately define your firm's label control and storage within the Labeling Production Area prior to approval and release.

AMENDMENT 1

This is a repeat observation.

Inspection Nov 16, 2022 to Dec 14, 2022: 3 observations

Firm on the cover
Wells Pharma of Houston LLC, 9265 Kirby Dr, Houston, TX 77054 -2520
FEI number
3016710931
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Routine inspection and checking of automatic and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically your firm failed to adequately validate the electronic building monitoring system, <Redacted B4> <Redacted B4> prior to use. Your firm uses the system to control, monitor, and record differential pressure, temperature, and relative humidity for the ISO classified along with non-classified areas used in the production of sterile and non-sterile drug products. For example, your firm initially validated the <Redacted B4> on 3/10/2020 with the revalidation not being approved until 12/15/2021. Your firm's VP of Quality reported following a review of the validation report by your firm's quality unit, a re-validation was required. In my review of the initial documented <Redacted B4> Validation Report, I found it failed to it failed to include documented differential pressure measuring, monitoring, and recording as pait of the system's qualifications, IQ, OQ, and PQ along with providing adequate data in support of the system qualification. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Buildings used in the manufacture, processing, packing, or holding of a drug product do not have the suitable construction to facilitate cleaning, maintenance, and proper operations.

Specifically, during a walk-through of your firm's cleanroom and visual inspection of the ISO 8 <Redacted B4> I observed a gap, approximately 0.5 inches from the bottom of the <Redacted B4> to the floor in both the controlled non-classified pre-production side and the ISO 7 Cleanroom side of the unit. Your firm failed to ensure the <Redacted B4> was not a potential source of lower quality air being transfened from the controlled non-classified production prep area into the higher quality air ISO 7 Cleanroom containing <Redacted B4> LAF units used in the aseptic processing of sterile drug products in the prevention of possible contamination resulting from the gap.

Observation 3

The responsibilities and procedures applicable to the quality control unit are not in writing.

Specifically, your firm's procedures, <Redacted B4>, HOU-QA-050 and Temperature, Humidity and Pressure Monitoring of Classified Areas, HOU-QC-002 used to document your firm's building monitoring systems environment conditions controls and monitoring requirements (differential pressure, temperature, and relative humidity) are inadequate. Your firm's procedure fails to adequately define and document differential pressure specifications, alert, and action limits for your firm's ISO 8 Anteroom, ISO 8 Gowning Room, and ISO 7 Cleanroom, which contain your firm's <Redacted B4> LAF units used in processing of aseptic sterile to sterile finished drug transfers along with sterile drug repackaging.

Inspection May 25, 2021 to Jun 17, 2021: 1 observation

Firm on the cover
Wells Pharma of Houston L LC, 9265 Kirby Dr, Houston, TX 77054-2520
FEI number
3016710931
Establishment type on the cover
Outsourcing P harmacy
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, there is no assurance that unidirectional airflow is maintained in the ISO 5 laminar air flow workbenches where sterile, injectable drug products are compounded.

I reviewed the smoke study dated 2/4/2021 for Laminar Air Flow Workbench #EQ-HOU-LAFW-067 and noted that first air was striking the stainless steel shelf inside the ISO 5 hood before sweeping down across aseptic connections and then recirculating beneath the same stainless steel shelf.

Linked 483s whose text is not shown

State board of pharmacy records

No license with this exact name and city was found in the Texas State Board of Pharmacy file dated Nov 15, 2026. A pharmacy can hold its license under a different legal name, so this is not a finding that it is unlicensed. Board file.

What this covers: The file marks whether a license has prior disciplinary orders (column DISP ACTN, Y or N) but does not list them; the orders are on the board’s license lookup, which this index does not copy. The board says orders entered more than 10 years ago are not online.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

LicenseType as the board gives itName on the board recordLocationStatus
NSF 144Nonresident Outsourcing FacilityWells Pharma Of Houston LlcHouston, TXDelinquent

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0012567Non Resident PharmacyWells Pharma of Houston, LLCHOUSTON, TXActive
AA-0010071Outsourcing Facility-PharmacyWells Pharma of Houston, LLCHOUSTON, TXActive

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301012826PharmacyWells Pharma of Houston, LLCHouston, TXActive

FDA’s 503B list

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming semaglutide under the labeler name “Wells Pharma of Houston”, matched to this pharmacy page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.

FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.

Reporting periods
73702-197SemaglutideSemaglutide injectionINJECTIONINTRAMUSCULAR2.5 mg/1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.